Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in Europe EMA Confirms Single HER2CLIMB Trial, If Positive, Could Support Approval

SEATTLE, July 11, 2017 – Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the outcome of discussions with the European Medicines Agency (EMA) regarding the development of tucatinib, an investigational medicine for the treatment of HER2- positive metastatic breast cancer. Following these discussions, the Company has received confirmation that positive results from its ongoing pivotal trial of tucatinib, known as HER2CLIMB, could serve as a single registrational trial for submission of a Marketing Authorization Application (MAA) to the EMA and potential marketing approval. The Company had received similar confirmation from the U.S. Food and Drug Administration (FDA) in 2016. “Our interactions with regulators in the U.S. and Europe continue to support the design of our pivotal trial as a registrational pathway for tucatinib in both regions,” said Marc Lesnick, Ph.D., Senior Vice President Regulatory Affairs and Quality at Cascadian Therapeutics. “We look forward to continued productive discussions in our future interactions with the EMA, the FDA and other health authorities.” Scott Myers, President and Chief Executive Officer, Cascadian Therapeutics, added, “This is an important milestone for the company. We had anticipated providing an update on our European regulatory strategy later this year; and we are pleased with this early feedback from the EMA that the current design of the global HER2CLIMB trial, if positive, could support approval and a potentially shorter path to the European market for tucatinib. Site and patient enrollment is currently ahead of schedule in North America, and we are now poised to begin enrolling patients in HER2CLIMB in other countries.”

About Tucatinib

Tucatinib is an investigational, orally bioavailable, potent tyrosine kinase inhibitor that is highly selective for HER2 without significant inhibition of EGFR. Inhibition of EGFR has been associated with significant toxicities, including skin rash and diarrhea. Tucatinib has shown activity as a single agent and in combination with both chemotherapy and other HER2 directed agents such as trastuzumab.1,2 Studies of tucatinib in these combinations have shown activity both systemically and in brain metastases. HER2 is a growth factor receptor that is overexpressed in multiple cancers, including breast, ovarian and gastric cancers. HER2 mediates cell growth, differentiation and survival. Tumors that overexpress HER2 (HER2-positive) are more aggressive and historically have been associated with poor overall survival, compared with HER2-negative cancers. 

About HER2CLIMB

Pivotal Trial HER2CLIMB is a randomized (2:1), double-blind, placebo-controlled pivotal clinical trial comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab and without loperamide or budesonide prophylaxis, in patients with locally advanced or metastatic HER2-positive breast cancer who have had prior treatment with a taxane, trastuzumab, pertuzumab and ado-trastuzumab emtansine, also known as T-DM1. The primary endpoint is progression-free survival (PFS) based upon independent radiologic review. Key objectives related to assessing activity in brain metastases include a key secondary endpoint of PFS in a subset of patients with brain metastases. All patients will be followed for overall survival. HER2CLIMB is 2 currently enrolling patients in the United States, Canada, Western Europe and Australia. Additional information is available at www.HER2CLIMB.com. 

About HER2-Positive Metastatic Breast Cancer 

Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the aggressive spread of cancer cells. The American Cancer Society estimates that 20-25 percent of the approximately 246,660 annual new cases of breast cancer diagnoses in the U.S. are HER2-positive. Historically, HER2 disease has been associated with shorter survival times as well as a higher risk of recurrence and CNS disease (brain metastases). Approximately 30 to 50 percent of HER2-positive breast cancer patients develop brain metastases over time.3,4 Over the past two decades, the approvals of four targeted treatments (trastuzumab, pertuzumab, lapatinib, and T-DM1) have led to improved time to progression and survival rates of patients with HER2-positive breast cancer. Despite these advances, there is still a significant need for new therapies that can impact metastatic disease, including brain metastases, and be tolerated for longer periods of time. 

About Cascadian Therapeutics 

Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.

 

Forward-Looking Statements

 

In order to provide Cascadian Therapeutics' investors with an understanding of its current results and future prospects, this release contains statements that are forward-looking. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," “could” and similar expressions are intended to identify forward-looking statements. These forward-looking statements include Cascadian Therapeutics' expectations regarding clinical development activities, timing of additional data, potential benefits of its product candidates, results of clinical trials of tucatinib, and the potential regulatory approval of tucatinib. Forward-looking statements involve risks and uncertainties related to Cascadian Therapeutics' business and the general economic environment, many of which are beyond its control. These risks, uncertainties and other factors could cause Cascadian Therapeutics' actual results to differ materially from those projected in forwardlooking statements, including the risks associated with the costs and expenses of developing its product candidates, the adequacy of financing and cash, cash equivalents and investments, changes in general accounting policies, general economic factors, achievement of the results it anticipates from its preclinical development and clinical trials of its product candidates, the receipt of regulatory approvals, and its ability to adequately obtain and protect its intellectual property rights. Although Cascadian Therapeutics believes that the forward-looking statements contained herein are reasonable as of the date hereof, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of Cascadian Therapeutics' risks and uncertainties, you should review the documents filed by Cascadian Therapeutics with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Cascadian Therapeutics does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except to the extent required by law.

References: 1. Moulder, S. et al., Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer. Clin Cancer Res, May 2017. 2. Hamilton, E. et al., Efficacy of a Phase 1b Study of Tucatinib (ONT-380), an Oral HER2-Specific Inhibitor, in Combination with Capecitabine and Trastuzumab in HER2+ Metastatic Breast Cancer, Including Patients with Brain Metastases. Presented at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting 2016, San Antonio, TX, December 9, 2016 (Poster P4-21-01). 3. Metro, et al., Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Annals of Oncology, vol. 212, no. 3, pp. 625-630, 2011. 4. Ramakrishna N., et al., Journal of Clinical Oncology 32, no. 19 (July 2014) 2100-2108. Source: Cascadian Therapeutics, Inc.

 # # #

 Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 mgreer@cascadianrx.com

Get Busy Living Podcast

Available on iTunes
Buzzsprout Page

Join us on the latest podcast episode of Tigerlily Foundation​'s MY LIFE Matters as Host, Erin,  chats with Lisa Quinn about how to get busy living after a stage 4 cancer diagnosis.

breastcancerMBCmetastaticmetastasisfamilycancerwomenstrengthyoungadvocateadvocacymylifemylifematterstigerlilyinspirationstrengthovercomeparentingchildrentipsadvicelife

Kelli Parker's MY LIFE Matters Podcast

Available on iTunes

Join us on the latest podcast episode of  the Tigerlily Foundation​'s MY LIFE Matters as Host, Erin McCarthy Azuse​ chats with Kelli Parker, a fierce advocate, loving mother, and beloved member of the MBC community.

 #MBC #MYLIFE #MYLIFEMATTERS #TIGERLILYFOUNDATION #MBC #METS #METASTATIC #PODCAST #CANCERPODCAST #CONNECT #TLF #METSMONDAY #IAMSUSAN #STAGE4 #STAGEIV #DONTIGNORESTAGE4 #INSPIRATION #KELLI

Brain Metastasis Research: A Summary of Two Recent Reviews

Many types of cancer are capable of spreading or metastasizing to the brain including lung, breast, melanoma and colorectal cancer. There is no cure for metastatic cancer of any type, but treating brain metastasis poses unique challenges.

In two recent review articles, President-Elect of the Metastasis Research Society, Dr. Dihua Yu, and colleagues discuss what is currently known about the complex biology of brain metastasis and which therapies or strategies are most promising.

The brain is unique.  It supports and preserves neuron functions with a network of specialised cells including astrocytes and microglia, and is protected by the ‘blood-brain barrier,’ which separates the brain from the circulating bloodstream.  

So how do cancer cells survive in the foreign environment of the brain and grow into metastatic brain tumors? Simply put, these cells are endowed with aggressive traits that enable them to cross the blood-brain barrier, escape recognition by anti-cancer immune cells in the brain, use the existing brain vasculature for nourishment, and they can even ‘educate’ other normal cells in the brain to support their growth and survival.  

Unfortunately, the aggressive traits of metastatic brain tumors can also make them resistant to standard systemic cancer therapy. In addition, more than 80% of patients with metastatic brain cancer already have multiple metastatic tumors at the time of diagnosis, making them ineligible for surgery.

Dr. Yu and colleagues note that the support of cancer growth in the brain by surrounding resident brain cells is a major contributor to therapy resistance.  Therefore, counteracting the ability of metastatic cancer cells to communicate with resident cells of the surrounding microenvironment should increase the clinical benefit of standard therapies.

It may also be possible to target the unique metabolic needs of brain metastatic cancer cells therapeutically.   Metastatic cancer cells must alter their metabolism to survive and grow in the brain.  For example, cancer cells can adapt to use neurotransmitters of the brain as metabolites.  Cancer cells may also become addicted to certain metabolites that could potentially be limited. But, the concept of targeting metastatic cancer cell metabolism isn’t ready for primetime in the clinic because many aspects of these molecular pathways still need to be clarified.

Much insight in the field of brain metastasis is expected to come from studies with preclinical models that recapitulate the entire metastatic process, and the intimate interactions between tumor cells and cells within the tumor microenvironment (cells in the area surrounding the brain tumor). Moreover, advancements in neuroimaging techniques are providing new tools for live imaging.  This technology is increasing our understanding of metastasis in experimental models and improving diagnostics in patients.

The extensive characterization of genes (genomic characterization) and molecules that are transcribed from genes to create proteins (transcriptomic characterization) in metastatic tumors isolated from patients is also providing clues to how tumor cells that metastasized to the brain differ from normal cells and from each other.  Tumor cells may be heterogeneous (different) and endowed with different molecular features and abilities even if they are within the same tumor. 

With this information, new hypotheses on the molecular mechanisms that orchestrate the establishment and progression of brain metastases are developing and creating new opportunities to find therapies that target a specific molecular feature of brain metastatic cancer cells.

In addition to targeted molecular therapies, immunotherapies are emerging as a potentially efficacious strategy for the treatment of brain metastases.  These therapies don’t target brain metastatic cancer cells themselves, but instead enhance the function of immune cells to suppress tumor growth.  Clinical investigations are now demonstrating that the ability of immune checkpoint inhibitors to effectively inhibit metastatic brain tumors is similar to their ability to treat metastatic tumors outside of the brain.  However, they could produce severe side effects.  This concept is explored in another article here.

Despite encouraging progress in this field, the clinical management of patients with brain metastases is still challenging and financial support for studies on metastatic cancers is limited. Further effort is required and active cooperation among biologists, neuroscientists and oncologists is the key to targeting metastatic cells early and from different fronts.  

Source Articles:

C. Zhang and D. Yu. Advances in decoding breast cancer brain metastasis. Cancer Metastasis Reviews. 2016. 35:677-684.

F.J. Lowry and D. Yu. Brain metastasis: unique challenges and open opportunities. Biochimica et Biophysica Acta. 2017. 1867:49-57.

About the Metastasis Research Society

The Metastasis Research Society (MRS) is a 31 year-old, non-profit, international professional society for researchers, clinicians, members of industry, and entrepreneurs who are dedicated to solving the problem of cancer metastasis.  The mission of the MRS is to support progressive research on any processes fundamental to metastasis. This includes supporting the exchange of information between all stakeholders in metastasis research and treatment via conferences, networking events, webinars, and the two official journals of the society (Clinical and Experimental Metastasis and Cancer and Metastasis Reviews).  We also strive to educate the public about metastatic cancer, and raise awareness about the funding discrepancy for metastatic research worldwide.


We encourage you to join our efforts and support metastatic cancer research and metastatic patient education globally by becoming an MRS member.  Click here to view membership categories and benefits, and join today.  Follow the MRS on Facebook and Twitter for up-to-date metastasis-related news.  Email metastasis.research@gmail.com for more information.

Northwest Arkansas Metsquerade

How the Northwest Arkansas Metsquerade came to be:

Pink ribbons are all around us in October and April announcing the seasons of Breast Cancer “awareness” throughout the country. Hundreds of millions of dollars are raised nationally for Breast Cancer, but a very small portion of this money is being allocated for Metastatic Breast Cancer (MBC). And while there is plenty of giving going on, there are very few advocates and organizations for MBC. One of our local outspoken advocates is Kelli Parker of Bella Vista, Arkansas. She was diagnosed at 26 with stage 1 breast cancer and metastasized to stage 4 by the age of 33. She did everything the early detection/awareness campaigns said she was supposed to do—double mastectomy, chemotherapy, radiation, hysterectomy, hormonal therapy, and more. Kelli realized that the current awareness and early detection approach is not working and is fighting for Metastatic Breast Cancer patients around the country and world.

One of the organizations she supports is METAvivor, a non-profit run primarily by women with MBC, which uses 100% of donations for research. 100%–this is unheard of in the non-profit sector. Imagine donating money to an organization that will maximize every dollar toward its goal. Knowing that the only key to making MBC a controllable chronic illness instead of a terminal one is more research, Kelli decided to throw her support to METAvivor.

In 2016 she came up with The First Annual Northwest Arkansas METSquerade idea as a way for the local community to specifically support the individuals with the only breast cancer that kills. She joined forces with another Northwest Arkansas woman with MBC, Lisa Quinn, to help make the Metsquerade happen. Lisa, age 37, was diagnosed with MBC in July 2015. She had no previous history with breast cancer. The idea behind the Metsquerade is to provide METAvivor with additional money to help research MBC, raise awareness to MBC, and to acknowledge the women and men living with metastatic breast cancer.

2016 Success

The 2016 Metsquerade was an enormous success! The event raised over $130,000 and was able to donate over $100,000 after event costs to Metavivor. The amount of money raised in the first year will fund two years of metastatic breast cancer research.

2016 Sponsors

The 2016 NWA Metsquerade sponsors included Diamond Sponsor 40/29, Gold Sponsors Coldwell Banker Harris McHaney & Faucette Real Estate & Embassy Suites, Silver Sponsors Slim Chickens, Hunt Ventures, & Walmart, Elite Sponsor Harps Foods, and Plus Sponsor Highlands Oncology.

About METAvivor

“METAvivor is dedicated to the specific fight of women and men living with stage 4 metastatic breast cancer. At the time of METAvivor’s founding, no organization was dedicated to funding research for the disease and no patient groups were speaking out about the death of stage 4 cancer research. While more and more people have taken up the cry for more stage IV research, METAvivor remains the sole US organization dedicated to awarding annual stage IV breast cancer research.”

METAvivor’s Mission

“METAvivor exists to sustain hope for those living with metastatic breast cancer (MBC). Passionately committed patients ourselves, we rally public attention to the urgent needs of the MBC community, help patients find strength through support and purpose, and make every dollar count as we work with researchers to regain longevity with quality of life.”

What METAvivor Does

Awareness

“We bring attention to the specific issues of stage 4 metastatic breast cancer, and raise public awareness about the facts of the disease. With 30% of breast cancer patients metastasizing, our goal is to see to it that 30% of breast cancer support and funding for research is dedicated to metastatic breast cancer.”

Research

“METAvivor awards research grants to individuals with a clinical or other doctoral degree who are actively engaged in areas of metastatic breast cancer research and whose proposals show distinct promise in making a difference for the stage 4 breast cancer community. The goal of our funding efforts is to transition metastatic breast cancer from a terminal diagnosis to a chronic, manageable disease with a decent quality of life.”

Funding

“METAvivor is run entirely by volunteers, most of who are living with metastatic breast cancer. Although we do not pay any salaries, we work to obtain grants and corporate sponsors to support our operation expenses. This allows us to ensure that donations can be entirely dedicated to our research grants that fund the cutting edge research that will ultimately save lives. Unless otherwise specified by the donor, 100% of every donation and 100% of proceeds from every fundraiser (after event expenses) goes into our research grants.”

To donate, attend, or learn more, please visit the NWA Metsquerade event page.

Self-advocacy and Parenting with Cancer Podcast

Available on iTunes
Buzzsprout Page


Join us on the fifth podcast episode of Tigerlily Foundation​'s MY LIFE Matters as Host, Erin,  chats with Jennifer Campisano about how to be your best advocate and overcoming the hurdles of parenting after a cancer diagnosis.


breastcancerMBCmetastaticmetastasisfamilycancerwomenstrengthyoungadvocateadvocacymylifemylifematterstigerlilyinspirationstrengthovercomeparentingchildrentipsadvicelife

Rebecca's Ode to Beth Calabotta

I don’t know what to do so I’m doing this, I’m writing. I am consumed by that horrible, helpless feeling that comes when someone you love is suffering and there is nothing you can do to stop it. I can stand here from across the country and connect with other people in her life and let her know that we are praying for her, thinking of her, crying for her, loving her, and staying present for her as much as we possibly can at this difficult time. I want to honor my friend Beth and let her know how loved she is by so many people. I want her to know what an impact she has had on this horrible disease. She has educated so many about the realities of metastatic breast cancer. She has bravely shared her story, time, DNA, brilliant mind and so much more to help prevent others from suffering as she has. I want her to know what an impact she has had on me. Her fierce, unwavering determination and dedication to do as much as we can as fast as we can to eradicate MBC energizes me every step of the way in fighting for this cause. So many of her brilliant ideas have helped shaped how I think about the disease and how we need to research and fund it. Beth thinks big but then she takes the time to attend to details and to people. She has no ego, no stake in any of it. Beth has known for some time that she would not benefit from the research and advocacy she has done so much to advance. Yet, even in her darkest hours, her most painful moments, she is still churning out ideas, emails, phone calls to help prevent others from experiencing this suffering. She is one of those rare individuals who is not only beloved by the entire MBC community and beyond, but she is truly revered. She is universally respected and admired as well as loved – and that is no small thing.

I went swimming the other day at an indoor pool. I mean really swimming – like actual laps – not just wading my cankles in to cool off kind of swimming. I thought of Beth the whole time. I hadn’t swam laps in years, but my doctors keep recommending it because of the severe joint pain I have caused by the cancer meds. As I eased into the rhythmic breathing and movements of my limbs gliding through the soft water – it occurred to me how much this sport – that she loved so much – suited Beth. Swimming is a tough sport. You have to be strong. You have to work at it to build stamina. You have to be dedicated. You have to know how to stay afloat and move at the same time. You have to multi-task – breathe, move, rotate, kick, pull, flip, push and glide. It is silent and often solitary – although Beth formed an incredible camaraderie with her swimming pals with whom she has strong and unbreakable bonds. You have to think, or deliberately not think as there are few distractions. You have to be self-reliant, driven, disciplined and self-motivated. It is for people with strong minds, bodies and hearts. Someone like Beth.

I don’t know what to do, but I know that I want to let Beth know all of these things that I think about her. I want her husband Dave, and her parents and her family to know all of this and more, what so many others think about our beloved Beth Calabotta.

I asked a small group of people in the MBC community who know and love Beth as I do, to each give me a word to describe her. This is what I got back.

Beth Calabotta believed in me and in The Cancer Couch from its infancy. She encouraged me, helped me, rallied around this foundation, and played a huge role in getting us where we are today and where we are going. Beth generously donated the funds from her annual Beth Calabotta Swim Challenge to The Cancer Couch. Planning is already underway for this year’s swim, not only in Illinois, but also here in CT  – my sister and her amazing crew in Cheshire are hosting a Beth Calabotta Swim Challenge in her honor.

If you would like more information on hosting a swim challenge of your own for The Cancer Couch in Beth’s honor, or participating in one, contact carrie@wellnessdatasolutions.com or vmciampi@gmail.com. A portion of the proceeds from all the swim challenges will go back to the fund set up in Beth’s name at Blessing Hospital in Quincy, Illinois as an angel fund to help MBC patients in financial need. A brick is also being placed in the garden there in Beth’s honor.

Beth, you make me want to swim.

You make me want to never stop fighting for MBC funding and advocacy.

You make me want to be a better person.

Thank you for giving all of us a shining example of the very best a human being can be.

I love YOU to the moon and back my friend.

https://thecancercouch.com/

Preserving Fertility in Women Undergoing Chemotherapy

Infertility caused by chemotherapy is an unfortunate problem that many cancer patients face. Although chemotherapy can be effective for treating cancer in young women and girls, their ability to conceive following chemotherapy is markedly reduced. A 2010 study conducted at UCSF found that up to 23% of women can have trouble conceiving after chemotherapy, yet only 5% received fertility counseling, and only 4% took action to preserve their fertility.

Ovaries are particularly sensitive to and are more affected by chemotherapy, which can irreversibly damage oocytes (eggs) and the ovarian follicles they develop in. This is why chemotherapy is described as gonadotoxic. However, several options are currently available to preserve fertility in women with cancer to give them the opportunity to become mothers after undergoing chemotherapy. These options include embryo freezing, oocyte freezing and ovarian autotransplantation.
In a 2015 Cancer and Metastasis Reviews article (a journal associated with the Metastasis Research Society) Dr. Teresa K. Woodruff and colleagues describe what ovarian autotransplantation is and discuss its' advantages and disadvantages. We are summarizing the information in this article now with the hope that it will encourage women undergoing chemotherapy to talk to their oncologists about fertility options and enable them to make more informed choices regarding their reproductive future.

The process of autotransplantation involves freezing a patient’s ovarian tissue, storing it while the patient undergoes chemotherapy, and then transplanting it back into the patient to allow them to resume regular reproductive function. The procedure is approved for teenage girls and young women (approximately age 15-42), especially those undergoing gonadotoxic treatments for cancers such as breast cancer.
Ovarian autotransplantion is considered the most promising procedure for preserving fertility in comparison to embryo and oocyte freezing because: (i) it does not require additional procedures, (ii) it allows patients to begin chemotherapeutic treatment immediately, and (iii) it can restore full reproductive functionality after cancer treatment. So far, autotransplantation has resulted in 40 healthy babies worldwide.
However, ovarian autotransplantation is not a technically easy procedure. It is a very sophisticated procedure that requires a highly skilled team of oncologists, gynecologists, biologists, and surgeons, and it may not be suitable for all patients. One of the major challenges is avoiding the reintroduction of cancer cells into the body of the woman. It is critical to thoroughly analyze samples of the tissue to be transplanted for any sign of remaining tumor cells.

Still, ovarian autotransplantation is an exciting and promising option for fertility preservation and offers a beacon of hope for female cancer patients. Researchers are actively working together to further guarantee the preservation of a woman’s fertility and we are making great strides. Now, we also need to raise awareness among young women in the cancer community so that they know to discuss fertility options with their doctors prior to undergoing cancer therapies such as chemotherapy that are known to be toxic to the reproductive system.


Senior Editor:
Kate Bankaitis PhD

Article Provided by Metastasis Research Society


The Metastasis Research Society (MRS) is a 31 year-old, non-profit, international professional society for researchers, clinicians, members of industry, and entrepreneurs who are dedicated to solving the problem of cancer metastasis. The mission of the MRS is to support progressive research on any processes fundamental to metastasis. This includes supporting the exchange of information between all stakeholders in metastasis research and treatment via conferences, networking events, webinars, and the two official journals of the society (Clinical and Experimental Metastasis and Cancer and Metastasis Reviews). We also strive to educate the public about metastatic cancer, and raise awareness about the funding discrepancy for metastatic research worldwide.

We encourage you to join our efforts and support metastatic cancer research and metastatic patient education globally by becoming an MRS member. Click here to view membership categories and benefits, and join today. Follow the MRS on Facebook and Twitter for up-to-date metastasis-related news. Email metastasis.research@gmail.com for more information.